Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03121092 · ClinicalTrials.gov registry record · NA

ACEI/ARB Study in Ambulatory and Day of Surgery Admission Patients

A NA study, sponsored by State University of New York - Downstate Medical Center.

Terminated
Registry status
NA
Development phase
188
Enrollment target

NCT03121092 is a NA study that was terminated before completion, run by State University of New York - Downstate Medical Center. The registered enrollment target is 188 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03121092, a NA study, was terminated before completion, sponsored by State University of New York - Downstate Medical Center.

TERMINATED
Registry status
NA
Development phase
188 participants
Enrollment target

Study Summary

Angiotensin converting enzyme inhibitors (ACEI's) and Angiotensin receptor blockers (ARB's) are commonly used anti-hypertensive medications that may have implications on the management of a patient undergoing surgery. Limited research has looked at the effects of these medications on perioperative complications and mortality. Some studies conducted on small groups of inpatients with advanced vascular disease undergoing vascular surgery or coronary artery bypass grafting (CABG), suggest exacerbation of hypotension (low blood pressure) in patients who continued taking ACEI's or ARB's on the morning of their procedure. In addition, cases of low blood pressure (BP) that were refractory to standard treatment were reported. One recent retrospective study reported no difference in severe hypotension and only a modest difference in moderate hypotension managed by conventional treatment, but did not adequately address the risk of preoperative hypertension. A study recently published by the investigators (Twersky et al., 2014) in over 600 patients demonstrated no difference in preoperative hypertension in ambulatory surgery and same day admission patients. There has been limited data stratifying the degree of low BP based on severity but these were not done in ambulatory patients, and neither was the degree of high BP from discontinuing these medications addressed. As such, no uniform consensus has been reached and clinicians are unclear as to whether the reported inpatient findings are applicable to the outpatients, since they differ in many respects. The investigators propose to evaluate whether ACEI's and ARB's discontinued preoperatively have a negative impact on perioperative hemodynamics and patient outcome in a group of ambulatory and same day surgical patients. Similar to studies done on inpatients, the investigators will also evaluate patients receiving a standardized general anesthetic for hemodynamics following induction of anesthesia until surgical incision. The

Interventions

  • DRUG ACEI or ARB

Trial Details

FieldValue
Enrollment Target 188 participants
Start Date 2012-05-16
Est. Completion 2017-03-07
Phase NA

What the Registry Record Tells You About NCT03121092

The ClinicalTrials.gov registry entry for NCT03121092 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 188 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is State University of New York - Downstate Medical Center, which has 18 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which ACEI or ARB is the first listed.

NCT03121092 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03121092 about?

NCT03121092 is a clinical study titled "ACEI/ARB Study in Ambulatory and Day of Surgery Admission Patients". Angiotensin converting enzyme inhibitors (ACEI's) and Angiotensin receptor blockers (ARB's) are commonly used anti-hypertensive medications that may have implications on the management of a patient undergoing surgery. Limited research has looked at the effects of these medications on perioperative c...

What is the current status of trial NCT03121092?

This trial is currently terminated. It is a NA study. The enrollment target is 188 participants. The study started on 2012-05-16. Estimated completion is 2017-03-07.

What interventions are being tested in trial NCT03121092?

The interventions under investigation include: ACEI or ARB (DRUG).

Who is sponsoring clinical trial NCT03121092?

This trial is sponsored by State University of New York - Downstate Medical Center, which has 18 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.